1. Medtech Insight
  2. >>Leadership

Q&A: AdvaMed Accel's Shadan, Wittorf Outline Lobbying Priorities, More

In a podcast exclusive with Medtech Insight, the new chair and executive director of small-company-focused AdvaMed Accel discussed their priorities for supporting small medtech companies. Among the topics discussed were the medical device tax, reimbursement uncertainty and empowering women in the industry.

Exclusive interview Q&A KOI

Martha Shadan, the new chair of AdvaMed Accel, and its executive director, Ashley Wittorf, recently sat down with Medtech Insight to discuss their lobbying priorities for small medtech companies. The two outlined their strategic goals to fight the medical device excise, reform the reimbursement processes and advocate for women in leadership positions in the medtech sector. (Also see "Shadan Brings Multi-Perspective View Of Medtech To AdvaMed Accel Chair Post" - Medtech Insight, 10 May, 2018.)

Listen to our interview in the player below and read a transcript of the Q&A:

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Leadership

More from Medtech Insight

Medtronic, Philips Cement New Pact To Embed Next-Gen Tech In Monitoring Platforms

 
• By Shubham Singh

Under the terms of the new agreement, Philips will also begin bundling essential supplies – including ECG, noninvasive blood pressure (NIBP) components, and batteries – with its Medtronic-enabled monitors.

Bivacor Rotary Heart Could Upend The Artificial Heart Market, If It Reaches Its Destination

 
• By Marion Webb

Bivacor aims to be first to the US market with a permanent total artificial heart, starting with use as a bridge to transplant. CMO William Cohn says data from countries with low transplant rates could support pivotal trials and long-term use.

Study: FDA’s Breakthrough Path Speeds Access, But Raises Safety Questions

 
• By Elizabeth Orr

Research recently published in JAMA Internal Medicine found that the FDA met its review timeline goals for the majority of breakthrough devices – but also revealed some apparent shortcomings in safety data supporting the submissions.